Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nestle´ Health Science and Chi-Med have agreed to form Nutrition Science Partners (NSP), a 50/50 joint venture(JV).
Subscribe to our email newsletter
The new entity will research, develop, manufacture and market new medicines and nutritional products derived from botanical plant origins globally, with focus on gastrointestinal indications and may also include metabolic disease and brain health areas in the future.
As part of the JV, Nestlé Health Science will make an initial capital investment in return for its 50%shareholding in NSP while Chi-Med will provide exclusive rights to its botanical library and botanical R&D platform, in the field of gastrointestinal disease.
Nestlé Health Science president and CEO Luis Cantarell said the JV provides Nestlé to develop and commercialise scientifically validated botanical based nutrition solutions for personalised healthcare in gastrointestinal health.
”The lead candidate HMPL-004 addresses key unmet GI needs for IBD patients," Cantarell added.
Chi-Med CEO Christian Hogg said, ”We are now joined in this important endeavour by Nestlé Health Science, and are confident that by harnessing the resources of our two groups, we will succeed in bringing a stream of novel botanical medicines and nutritional products to market and in-so-doing build significant value for patients and for our shareholders."
NSP, which will be funded primarily through Nestle Health Science capital investment, will also progress HMPL-004, a new oral therapy for inflammatory bowel disease through phase III trials.